載入...
Discontinuation of Imatinib Mesylate could Improve Renal Impairment in Chronic Myeloid Leukemia
We aim to report a CML case that had fluid retention and serum creatinine increase under long-term imatinib mesylate (IM) treatment. A 68-year-old woman was diagnosed with chronic myeloid leukemia, and IM was started in 2002 with a dose of 400 mg/day. She had achieved complete hematological, molecul...
Na minha lista:
| 發表在: | Open Med (Wars) |
|---|---|
| Main Authors: | , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
De Gruyter
2018
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6310919/ https://ncbi.nlm.nih.gov/pubmed/30613793 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1515/med-2019-0004 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|